“What we are trying to do more often is to ablate as much as we can,” said Shankar Siva, MBBS, PhD, FRANZCR, on pairing SABR with systemic therapy in RCC.
|Videos|August 1, 2017
Second-Line Therapy Options in Metastatic Renal Cell Carcinoma
Author(s)Neeraj Agarwal, MD
This video reviews the various treatment options for metastatic renal cell carcinoma in the second-line setting, including considerations for different toxicity profiles.
Advertisement
In this video, Neeraj Agarwal, MD, of the University of Utah Huntsman Cancer Institute, reviews the various treatment options for metastatic renal cell carcinoma in the second-line setting, including considerations of the different toxicity profiles.
Agarwal spoke on this topic at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting.
Advertisement
Related to this article
Triplets did not beat pembrolizumab plus lenvatinib in frontline RCC, while belzutifan plus lenvatinib and perioperative pembrolizumab showed benefit.
Advertisement
Advertisement
Trending on CancerNetwork
1
Petosemtamab/Pembrolizumab Improves OS in First-Line PD-L1–Positive HNSCC
2
Sacituzumab Govitecan PFS Benefit Holds Across Subgroups in Untreated mTNBC
3
Can a Selinexor Quadruplet Treat Myeloma After T-Cell Redirecting Therapy?
4
Breast Cancer Locator Noninferior to Wire Localization for Lumpectomy Margins
5